Results 151 to 160 of about 28,823 (297)

From biology to biotechnology: Host‐regulation factors from parasitoid wasps are a source of bioactive molecules with translational potential

open access: yesInsect Molecular Biology, EarlyView.
Parasitoid wasps deploy maternal and embryonic factors to reprogramme host physiology. Venom, calyx fluid, polydnaviruses, teratocytes and larval secretions act in a coordinated, compartmentalised manner. Host‐regulation factors are promising sources of insecticidal, antimicrobial and bioinspired translational molecules.
Ciro Pedro G. Pinto   +2 more
wiley   +1 more source

Cholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
This study reveals that monocyte cholesterol accumulation correlates with the severity of diabetic complications and predicts post‐discharge glycemic deterioration. These findings suggest that monocytic cholesterol serves as a novel translational biomarker reflecting ‘metabolic memory’ and therapeutic resistance in patients with type 2 diabetes ...
Hideyuki Okuma   +3 more
wiley   +1 more source

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2013
David ScottClinical Research Development Associates, Rosedale, NY, USAAbstract: Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide.
Scott D
doaj  

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

open access: yesJournal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi   +4 more
wiley   +1 more source

A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition

open access: yesТерапевтический архив, 2013
AIM: To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who ...
M V Shestakova   +6 more
doaj  

Continuous glucose monitoring–guided management of capivasertib‐associated hyperglycemia: A case series of three patients

open access: yesJournal of Diabetes Investigation, EarlyView.
Continuous glucose monitoring (CGM) visualized cyclic glycemic fluctuations associated with the 4‐days‐on/3‐days‐off capivasertib schedule. Compared with off‐treatment days, dosing days showed higher mean sensor glucose, greater coefficient of variation (CV), more time above 250 mg/dL, and lower time in range (TIR; 70–180 mg/dL).
Hiroki Okumura   +13 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

open access: yesJournal of the American College of Cardiology, 2012
openaire   +1 more source

The Upfront Effectiveness of a 6‐Week Continuous Glucose Monitoring Intervention for Non‐Insulin‐Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6–12 Months: An Observational Follow‐Up of a Randomized Trial Cohort

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Jiawei Ryan Zhang   +8 more
wiley   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

open access: yesJournal of Diabetes Investigation, EarlyView.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy